Leading with lung
Lung cancer, PD-1/PD-L1 take over ASCO
Lung cancer squeezed past breast cancer as the top indication at the American Society of Clinical Oncology meeting this year as targeted therapies duke it out within genetically defined subgroups, while immunotherapies seek their best molecular subpopulations, combination partner or both.
BioCentury analyzed the roughly 3,600 meeting abstracts related to clinical, preclinical, biomarker or basic cancer research released in advance of the meeting taking place June 2-6 in Chicago.
Analyses of the top indications and targets reflect a huge emphasis on the role of the immune system in cancer (see “Top Indications at ASCO” and “Top ASCO Targets”).
This is not a surprise, as checkpoint inhibitors and other immunotherapies have been the hottest programs in industry’s cancer pipeline for the past few years, and every company with a checkpoint inhibitor is testing it with multiple combination partners and across several types of cancer.
PD-1 and PD-L1 were each mentioned in roughly one-sixth of the lung cancer abstracts. These include clinical studies attempting to bring Opdivo nivolumab from Bristol-Myers Squibb Co. and Keytruda pembrolizumab from Merck & Co. Inc. up the lines of therapy or into new combinations.
However, immunotherapies only partly